Sequence: LLRLLRWWWRLLRLL
| Experiment Id | EXP002479 |
|---|---|
| Paper | In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Del |
| Peptide | WRAP5 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide:siRNA molar ratio R = 20; peptide concentration not separately reported. |
| Rna Concentration | |
| Mixing Ratio | WRAP5:siRNA molar ratio R = 20; preincubated 30 min at room temperature in 5% glucose. |
| Formulation Format | peptide-based nanoparticle / non-covalent CPP:siRNA complex |
| Formulation Components | WRAP5:siRNA peptide-based nanoparticles formulated in 5% glucose; peptide:siRNA molar ratio R = 20; siFluc or siSCR; fluorescent siFluc-Alexa790/Cy3 included for imaging in some experiments. |
| Size Nm | 80.00 |
| Zeta Mv | 28.80 |
| Model Scope | in_vivo |
| Model Type | in vivo subcutaneous U87 xenograft reporter silencing |
| Cell Lines Or Primary Cells | U87-CMV/Fluc+Nluc+ human glioblastoma cells |
| Animal Model | NSG mice bearing subcutaneous U87-CMV/Fluc+Nluc+ xenograft tumors |
| Administration Route | intratumoral injection |
| Output Type | in vivo reporter-gene knockdown |
| Output Value | ~70% reduction in Fluc/Nluc-normalized bioluminescence at day 1 after WRAP5:siFluc injection; Fluc mRNA reduced by qRT-PCR at day 2; fluorescence remained in tumor up to 10 days. |
| Output Units | |
| Output Notes | Functional in vivo reporter knockdown was demonstrated by bioluminescence imaging and qRT-PCR; Nluc served as tumor-growth/internal control. |
| Toxicity Notes | No toxicity reported; in vivo Fluc silencing occurred without apparent tumor-growth effect because this was a reporter proof-of-concept. |
| Curation Notes |